---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-239008"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:51:24.928930+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# EyePoint initiates Phase 3 DURAVYU DME program; first patient Q1 2026; dual MOA data

## Summary
- First patient dosing in pivotal Phase 3 DME trials (COMO and CAPRI) expected Q1 2026; trials enroll ~240 patients each.
- Non-inferiority design vs aflibercept; primary endpoint is BCVA change from baseline at weeks 52 and 56.
- New preclinical data shows vorolanib inhibits IL-6 mediated inflammation via JAK receptors, adding to VEGF blockade.
- Company had positive end-of-Phase 2 meeting with FDA; DURAVYU also in Phase 3 for wet AMD.
- Estimated cash and investments as of Sept 30, 2025 included in investor presentation (not specified).

## SEC filing metadata
- accession: 0001193125-25-239008
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312525239008/0001193125-25-239008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312525239008/d14832d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-239008
- JSON: https://secwatch.observer/filing/0001193125-25-239008.json
- Plain text: https://secwatch.observer/filing/0001193125-25-239008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.